MetaCap

Contineum Therapeutics (CTNM) vs Phathom Pharmaceuticals (PHAT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Contineum Therapeutics (CTNM) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 20.7% versus a loss of 68.9%. Phathom Pharmaceuticals is the larger company by market cap ($378.8 million vs $340.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CTNM-20.69%PHAT-68.93%
+67%-4%-75%
Nov 21, 20251 yearNov 20, 2026
CTNM-43.64%PHAT-57.75%
+74%-5%-84%
Apr 1, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CTNM versus PHAT key metrics
MetricCTNMPHAT
Share price$8.68$4.66
Market cap$340.83M$378.82M
1-day change-3.98%-8.27%
YTD return-24.06%-71.91%
1-year return-20.69%-68.93%
5-year return—-76.46%
Forward P/E—5.18
EPS (TTM)$-1.77$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$175.11M
Revenue growth (YoY)—+216.93%
Net income (latest FY)$-59.98M$-221.25M
Gross margin—87.09%
Operating margin—-91.36%
Net margin—-126.35%
52-week high$17.79$18.31
52-week low$6.73$4.62
Distance from 52-week high-51.19%-74.55%
Analyst consensusbuystrong_buy
Avg. price target upside+146.89%+321.67%
Average volume776.03K1.45M
Shares outstanding35.35M81.29M
Employees51371
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CTNM has outperformed PHAT by 48.2 percentage points over the past year.

About Contineum Therapeutics

CTNM stock →

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees

About Phathom Pharmaceuticals

PHAT stock →

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.

Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees

CTNM vs PHAT FAQ

Which is bigger, Contineum Therapeutics or Phathom Pharmaceuticals?

Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $378.82M compared with $340.83M for Contineum Therapeutics (CTNM).

Which stock has performed better over the past year, CTNM or PHAT?

CTNM returned -20.69% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.

Are Contineum Therapeutics and Phathom Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons